VitalCare Diabetes Treatment Centers, Inc.  is a Bio-tech company that is commercializing a cutting edge FDA approved technology for treating metabolic disorders specifically targeting Type 1 and Type 2 Diabetes and Secondary Complications of Type 2 Diabetes.  The Treatment is known as Intercellular Activation Therapy “iCAT” and uses an FDA approved, US and European patented micro-dose intravenous insulin pump combined with proprietary algorithms and peer reviewed clinical protocols. Business   Approximately 100,000 treatments spanning over the past 25+ years have been administered. proving the effectiveness of iCAT therapy with not one negative side effect or medical complication reported.  There are  a number of peer reviewed published articles by top medical researchers in the field of Diabetes, Wound Care and Endocrinology who've determined that iCAT Therapy is by far the most successful adjunct to traditional treatment for Secondary Complications of Type 2 Diabetes and  treatment for Type 1 and Type 2  Diabetes.    VitalCare entered into an exclusive Licensing Agreement with the manufacturer of the patented and FDA approved micro-dose intravenous insulin pump and the exclusive developer of the proprietary algorithms and clinical protocols, who provides ongoing clinical oversight, medical training and quality control services to all certified VitalCare Diabetes Treatment Centers and affiliates.   These exclusive licenses for North America include the USA, Canada and Mexico with further rights to expand internationally with some exclusions.   VitalCare will seek to open company owned VitalCare Diabetes Treatment Centers, identify and license the technology to healthcare specialists who meet stringent criteria for “Certification”, and license the iCAT Therapy to Insurance Plans and HMO’s under a Disease Management program. iCAT Therapy will  initially be introduced to the consumer market as a rescue treatment for “Brittle Diabetic” patients suffering from secondary complications of Type 2 Diabetes, to include; difficult to heal wounds, high blood pressure, heart disease, visual impairment and kidney disease, using the patented and FDA approved micro-dose intravenous insulin pump device.    Currently, there are approximately 30 licensed iCAT clinics operating in North America, including Florida, Arizona, Utah, California, Texas and Nevada.  VitalCare has an ownership joint-venture interest in two wound care centers in Indiana and has acquired joint ownership in the iCAT clinic located in Scottsdale, AZ.  VitalCare is currently in negotiations for acquisitions with an iCAT clinic in Sacramento, CA and one in Draper, UT.  VitalCare anticipates having clinics opened, either Company owned, joint venture or sub-licensed affiliates, in all fifty states by year end 2010.     Medical Devices iCAT is delivered exclusively with the FDA approved, US and European patented micro-dose intravenous insulin pump device sold via an exclusive purchasing agreement through VitalCare. In addition to licensing and distribution of the insulin pumps, VitalCare will also market and distribute metabolic carts used to measure the patient’s Respiratory Quotient (“RQ”).  In the future, VitalCare plans on licensing and marketing the proprietary pre-filled insulin cartridges that will operate only with VitalCare’s insulin pump technology. iCAT Therapy has been independently proven to be safe and effective for Type 1 and Type 2 Diabetes and most secondary medical complications of Type 2 Diabetes with additional Medical Patents issued for; cardiovascular disease, diabetic wounds, retinopathy, secondary hypertension and kidney disease.  In addition, iCAT Therapy has been found to improve all the general maladies of diabetes including lack of well-being, low energy, improving sleep, and there is anecdotal data on improvement in erectile dysfunction. iCAT Therapy has been proven safe and effective on the most difficult and critically ill patients who have failed all conventional therapies commonly referred to as “Brittle Diabetics”.  Both patients and their physicians see positive results within a few treatment sessions. There is currently no other therapy known to have this high degree of clinical outcomes at or exceeding iCAT Therapy, with a documented 93%+ clinical outcome for patients between  the ages of 5 years to 90+ years of age.